The closing price of Cano Health Inc. (NYSE: CANO) was $1.20 for the day, up 1.69% from the previous closing price of $1.18. In other words, the price has increased by $+0.0200 from its previous closing price. On the day, 6307992 shares were traded. CANO stock price reached its highest trading level at $1.2050 during the session, while it also had its lowest trading level at $1.1200.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Ratios:
Our analysis of CANO’s different ratios will help us gain a deeper understanding of the company. In the meantime, Its Debt-to-Equity ratio is 2.28 whereas as Long-Term Debt/Eq ratio is at 2.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on January 06, 2023, Downgraded its rating to Neutral and sets its target price to $1.25 from $12 previously.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 17 when Gold Lewis bought 300,000 shares for $6.81 per share. The transaction valued at 2,043,000 led to the insider holds 314,825 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.24 while its Price-to-Book (P/B) ratio in mrq is 0.69.
Stock Price History:
Over the past 52 weeks, CANO has reached a high of $9.75, while it has fallen to a 52-week low of $0.98. The 50-Day Moving Average of the stock is 1.4218, while the 200-Day Moving Average is calculated to be 4.0027.
Shares Statistics:
CANO traded an average of 8.65M shares per day over the past three months and 8.36M shares per day over the past ten days. A total of 232.31M shares are outstanding, with a floating share count of 185.31M. Insiders hold about 11.80% of the company’s shares, while institutions hold 68.60% stake in the company. Shares short for CANO as of Jan 30, 2023 were 25.37M with a Short Ratio of 28.03M, compared to 24.89M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 10.37% and a Short% of Float of 16.69%.
Earnings Estimates
The firm’s stock currently is rated by 6 analysts. On average, analysts expect EPS of -$0.13 for the current quarter, with a high estimate of -$0.02 and a low estimate of -$0.21, while EPS last year was $0. The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.01 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.36 and -$0.48 for the fiscal current year, implying an average EPS of -$0.43. EPS for the following year is -$0.27, with 6 analysts recommending between -$0.02 and -$0.59.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 9 analysts. It ranges from a high estimate of $676.47M to a low estimate of $632.18M. As of the current estimate, Cano Health Inc.’s year-ago sales were $492.25M, an estimated increase of 32.40% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $834.83M, an increase of 18.50% less than the figure of $32.40% in the same quarter last year. There is a high estimate of $883.55M for the next quarter, whereas the lowest estimate is $759.19M.
A total of 10 analysts have provided revenue estimates for CANO’s current fiscal year. The highest revenue estimate was $2.73B, while the lowest revenue estimate was $2.59B, resulting in an average revenue estimate of $2.7B. In the same quarter a year ago, actual revenue was $1.61B, up 67.80% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $3.25B in the next fiscal year. The high estimate is $3.33B and the low estimate is $3.08B. The average revenue growth estimate for next year is up 20.50% from the average revenue estimate for this year.
